267 related articles for article (PubMed ID: 22947300)
1. Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis.
Yang CC; Li SH; Chuang FR; Chen CH; Lee CH; Chen JB; Wu CH; Lee CT
BMC Infect Dis; 2012 Sep; 12():206. PubMed ID: 22947300
[TBL] [Abstract][Full Text] [Related]
2. Nosocomial extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia in hemodialysis patients and the implications for antibiotic therapy.
Yang CC; Wu CH; Lee CT; Liu HT; Chen JB; Chiu CH; Chen CH; Chuang FR
Int J Infect Dis; 2014 Nov; 28():3-7. PubMed ID: 25200093
[TBL] [Abstract][Full Text] [Related]
3. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.
Lee CH; Su LH; Tang YF; Liu JW
J Antimicrob Chemother; 2006 Nov; 58(5):1074-7. PubMed ID: 16971415
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
[TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC
J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244
[TBL] [Abstract][Full Text] [Related]
7. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
[TBL] [Abstract][Full Text] [Related]
8. Associated factors and clinical outcomes of bloodstream infection due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae during febrile neutropenia.
Ben-Chetrit E; Eldaim MA; Bar-Meir M; Dodin M; Katz DE
Int J Antimicrob Agents; 2019 Apr; 53(4):423-428. PubMed ID: 30572008
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications and risk factors of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection in children: a case-control retrospective study in a medical center in southern Taiwan.
Kuo KC; Shen YH; Hwang KP
J Microbiol Immunol Infect; 2007 Jun; 40(3):248-54. PubMed ID: 17639166
[TBL] [Abstract][Full Text] [Related]
10. [Bacteremia caused by Escherichia coli and Klebsiella pneumoniae producing extended-spectrum betalactamases: mortality and readmission-related factors].
Perianes-Díaz ME; Novo-Veleiro I; Solís-Díaz K; Prolo-Acosta A; García-García I; Alonso-Claudio G
Med Clin (Barc); 2014 May; 142(9):381-6. PubMed ID: 23735867
[TBL] [Abstract][Full Text] [Related]
11. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
[TBL] [Abstract][Full Text] [Related]
12. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.
Mosqueda-Gómez JL; Montaño-Loza A; Rolón AL; Cervantes C; Bobadilla-del-Valle JM; Silva-Sánchez J; Garza-Ramos U; Villasís-Keever A; Galindo-Fraga A; Palacios GM; Ponce-de-León A; Sifuentes-Osornio J
Int J Infect Dis; 2008 Nov; 12(6):653-9. PubMed ID: 18511321
[TBL] [Abstract][Full Text] [Related]
13. Risk factors and outcomes for bloodstream infections with extended-spectrum beta -lactamase-producing Klebsiella pneumoniae ; Findings of the nosocomial surveillance system in Hungary.
Szilágyi E; Füzi M; Böröcz K; Kurcz A; Tóth A; Nagy K
Acta Microbiol Immunol Hung; 2009 Sep; 56(3):251-62. PubMed ID: 19789140
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae.
Lee JA; Kang CI; Joo EJ; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Ko KS; Lee NY; Song JH
Microb Drug Resist; 2011 Jun; 17(2):267-73. PubMed ID: 21388296
[TBL] [Abstract][Full Text] [Related]
15. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Chopra T; Marchaim D; Veltman J; Johnson P; Zhao JJ; Tansek R; Hatahet D; Chaudhry K; Pogue JM; Rahbar H; Chen TY; Truong T; Rodriguez V; Ellsworth J; Bernabela L; Bhargava A; Yousuf A; Alangaden G; Kaye KS
Antimicrob Agents Chemother; 2012 Jul; 56(7):3936-42. PubMed ID: 22547616
[TBL] [Abstract][Full Text] [Related]
16. Klebsiella ESBL bacteremia-mortality and risk factors.
Tuon FF; Kruger M; Terreri M; Penteado-Filho SR; Gortz L
Braz J Infect Dis; 2011; 15(6):594-8. PubMed ID: 22218521
[TBL] [Abstract][Full Text] [Related]
17. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
[TBL] [Abstract][Full Text] [Related]
18. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia. Risk factors and clinical outcome.
Panhotra BR; Saxena AK; Al-Ghamdi AM
Saudi Med J; 2004 Dec; 25(12):1871-6. PubMed ID: 15711657
[TBL] [Abstract][Full Text] [Related]
19. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for and mortality of extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections.
Superti SV; Augusti G; Zavascki AP
Rev Inst Med Trop Sao Paulo; 2009; 51(4):211-6. PubMed ID: 19739001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
